SCHEMBL2354237

SCHEMBL2354237

Oc1nccc(-c2ccccc2F)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.47
MPL P40238 1/20 0.43
CDC7 O00311 1/20 0.43
DBF4 Q9UBU7 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 1/20 0.41
FEN1 P39748 2/20 0.41
IDO1 P14902 1/20 0.41
VCP P55072 1/20 0.40
PARP1 P09874 1/20 0.40
KMO O15229 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7471495 0.86 KMO (0.46) CDC7DBF4FEN1KMO
SCHEMBL30353577 0.81 FEN1 (0.57) NPC1MPLCDC7DBF4RAB9A
SCHEMBL5140478 0.81 FEN1 (0.57) NPC1MPLCDC7DBF4RAB9A
SCHEMBL28296096 0.81 NPC1 (0.50) NPC1MPLL3MBTL1CASP3SENP8
SCHEMBL29002136 0.78 HSP90AA1 (0.46) L3MBTL1ALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL11903404 0.78 ALDH1A1 (0.43) NPC1L3MBTL1RAB9AALDH1A1GAA
SCHEMBL15196256 0.78 NPC1 (0.47) NPC1MPLL3MBTL1CASP3SENP8
SCHEMBL2350242 0.78 NPC1 (0.47) NPC1MPLL3MBTL1CASP3SENP8
SCHEMBL27782182 0.76 KMO (0.68) NPC1CDC7DBF4RAB9APARP1
SCHEMBL23032100 0.74 NPC1 (0.44) NPC1MPLL3MBTL1CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008488-B2 Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands ABBOTT GMBH & CO. KG (DE) 2011-08-30 US disclosed
EP-1601659-B1 PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBOTT GMBH & CO KG (DE) 2008-01-16 EP disclosed
US-20060235004-A1 Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands ABBOT GMBH & CO. KG (DE) 2006-10-19 US disclosed
EP-1601659-A1 PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS Abbott GmbH & Co. KG (DE) 2005-12-07 EP disclosed
WO-2004080981-A1 PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBOTT GMBH & CO. KG (DE) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235004-A1 Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands ADRB3, DRD3, OPRL1 NPC1 2328/4885MPL 473/4885CDC7 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.